Eli Lilly & Co. LLY, +0.07% said Friday a late-stage trial of a treatment for a type of non-small cell lung cancer met its main goal. The Phase 3 trial dubbed Libretto-431 showed a statistically significant and clinically meaningful improvement in progression-free survival for Retevmo versus platinum-based chemotherapy in treating adults with rearranged during transfection (RET) fusion-positive advanced or metastatic non-small cell lung cancer. “The labeling for Retevmo contains warnings and precautions for hepatotoxicity (evidence of liver dysfunction), interstitial lung disease (ILD)/pneumonitis, hypertension, QT interval prolongation, hemorrhagic events, hypersensitivity, tumor lysis syndrome, risk of impaired wound healing, hypothyroidism, and embryo-fetal toxicity,” the company said in a statement. But the trial involving 261 patients in 16 countries and 85 sites, found durable responses across a variety of tumor types. Non-small cell lung cancer accounts for about 85% of all lung cancer diagnoses in the U.S. Eli Lilly plans to present the full data from the trial at an upcoming medical meeting, and to submit them to a peer-reviewed journal and discuss them with health authorities. The stock was slightly higher premarket and is up 23% in the year to date, while the S&P 500 SPX, -0.53% has gained 17%.
This article was originally published by Marketwatch.com. Read the original article here.
